Preferred Label : Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522;
NCIt synonyms : ADC XMT-1522; Anti-HER2 ADC XMT-1522;
NCIt definition : An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed
against the human epidermal growth factor receptor 2 (ERBB2; HER2), conjugated, via
a proprietary biodegradable, hydrophilic polymer backbone and various linkers, to
proprietary auristatin-derived payload molecules (about 15 per antibody), with potential
antineoplastic activity. Upon administration of anti-HER2/auristatin payload ADC XMT-1522,
the antibody moiety targets and binds to a unique epitope in the extracellular domain
(ECD) of HER2. Upon internalization, cleavage and release of the cytotoxic molecules,
the auristatin-derived molecules bind to tubulin and inhibit its polymerization, which
results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells.
The attachment of multiple auristatin molecules to the backbone enables XMT-1522 to
effectively kill tumors that express relatively low amounts of the HER2 protein; therefore,
this agent shows increased therapeutic potential in tumors with low HER2 expression
compared to other anti-HER2 antibody-based therapies. The polymer-based proprietary
platform optimizes delivery of the cytotoxic drug payload and improves drug solubility.;
Molecule name : XMT-1522;
NCI Metathesaurus CUI : CL520319;
Origin ID : C132112;
UMLS CUI : C4329330;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
